Humana Q1 EPS $10.31 Beats Estimates, Benefit Ratio at 89.4%
Humana delivered Q1 adjusted EPS of $10.31 on $39.65B revenue, surpassing consensus and driving a benefit ratio of 89.4%, below its sub-90% target. The insurer maintained its full-year adjusted EPS forecast of at least $9, lowered GAAP guidance to $8.36, and expects Q2 benefit ratio above 91%.
1. Q1 Financial Results
Humana reported Q1 adjusted EPS of $10.31 on revenue of $39.65 billion, exceeding analyst estimates by $0.11 per share and $0.28 billion. GAAP EPS stood at $9.83, compared with $10.30 in Q1 2025.
2. Benefit Ratio and Cost Management
The insurance segment benefit ratio was 89.4%, undercutting the sub-90% target through lower medical and pharmacy costs. Management projects the ratio to rise above 91% in Q2 due to evolving utilization and reimbursement trends.
3. Guidance and Outlook
The company reaffirmed full-year adjusted EPS guidance of at least $9 while lowering GAAP EPS forecast to $8.36 from $8.89. Enrollment in individual Medicare Advantage plans is expected to grow roughly 25% over 2026.
4. Strategic Initiatives and Clinical Improvements
Humana is shifting focus to the 2027 bid cycle with a goal of achieving a 3% Medicare Advantage margin by 2028. A centralized transformation office and enhanced clinical processes drove a 5% improvement in HEDIS gap closure pace for new members.